Market research
82P.F Pacira BioSciences, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 829M
- P/E ratio
- 69.33
- Analyst target
- 79
- Dividend yield
- Not available
- Beta
- 0.27
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US6951271005
- Market cap
- 829M
- P/E ratio
- 69.33
- Analyst target
- 79
- Dividend yield
- Not available
- Beta
- 0.27
About
About Pacira BioSciences, Inc
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 82P.F discussion.
5 years, 5 months ago
Pacira BioSciences, Inc is currently in a long term downtrend where the price is trading 11.4% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 7.0.
Pacira BioSciences, Inc's total revenue rose by 5.0% to $129M since the same quarter in the previous year.
Its net income has increased by 396.9% to $15M since the same quarter in the previous year.
Finally, its free cash flow grew by 50.7% to $32M since the same quarter in the previous year.
Based on the above factors, Pacira BioSciences, Inc gets an overall score of 4/5.